Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

54.32 -1.45 (-2.60%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,895,353
Open 55.88
Bid (Size) 54.28 (5)
Ask (Size) 54.68 (8)
Prev. Close 55.77
Today's Range 54.20 - 55.90
52wk Range 39.35 - 56.20
Shares Outstanding 2,222,113,553
Dividend Yield 4.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79. 
Via Investor's Business Daily
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline. 
Via Benzinga

Performance

YTD
+2.96%
+2.96%
1 Month
+0.22%
+0.22%
3 Month
+14.14%
+14.14%
6 Month
+23.74%
+23.74%
1 Year
+2.84%
+2.84%

More News

Read More
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
Via Benzinga
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Via Benzinga
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Via Benzinga
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
Via Investor's Business Daily
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
Markets Give Back Gains As Hovering Continues
Via Talk Markets
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Via Benzinga
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
What Lies In Store For Healthcare ETFs In Q3 Earnings?
Via Talk Markets
Topics ETFs
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
Via Benzinga
Why Is Evotec Stock Gaining Today?
Via Benzinga
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
Via Talk Markets
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
Via Benzinga
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Via The Motley Fool
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
Via Investor's Business Daily
Exposures Product Safety
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Via Talk Markets
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Via Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.